Nimotuzumab Injection

Get a Price/Quote

MOQ : 10 Boxes

Nimotuzumab Injection Specification

Salt Composition
Nimotuzumab

Indication
Treatment of certain head and neck cancers, glioma, nasopharyngeal carcinoma, and other epithelial cancers

Dosage Form
Injection

Enzyme Types
Monoclonal antibody (IgG1) - not an enzyme-based product, Monoclonal Antibody (Not an enzyme)

Feature
Humanized monoclonal antibody with high selectivity and reduced toxicity, Humanized monoclonal antibody with low immunogenicity

Ingredients
Nimotuzumab (recombinant humanized monoclonal antibody), excipients, Nimotuzumab (active ingredient), suitable excipients and preservatives

Application
Anticancer therapy, Oncology

Ph Level
Not applicable (biological injection)

Temperature Needed For Fermentation
Not applicable (biotechnology-derived)

Physical Color/Texture
Clear, colorless to pale yellow solution, Clear to slightly opalescent, colorless liquid

Fermentation Smell
Odorless, Odorless

Enzymatic Activity
Not applicable (antibody, not an enzyme)

Storage Instructions
Store at 2C to 8C. Do not freeze. Protect from light.

Shelf Life
24 months from date of manufacture

Contraindications
Known hypersensitivity to Nimotuzumab or any component of the formulation

Packaging Type
Vial

Mechanism of Action
Binds to human epidermal growth factor receptor (EGFR), inhibiting tumor growth

Prescription Status
Prescription only (Rx)

Route of Administration
Intravenous infusion

Preservatives
Contains suitable preservatives as per regulatory norms

Precautions
Use under strict medical supervision

Strength
50mg/10ml

Nimotuzumab Injection Trade Information

Minimum Order Quantity
10 Boxes

Payment Terms
Cash Against Delivery (CAD), Cash on Delivery (COD), Cash in Advance (CID)

Supply Ability
100 Boxes Per Month

Delivery Time
5-7 Days

Main Domestic Market
All India

About Nimotuzumab Injection

Experience the premier standard in oncology care with our top-rated Nimotuzumab Injection, 50mg/10ml, offered at the best price and designed for instant checkout. This ravishing therapeutic is dispensed in secure vials, containing suitable preservatives, and is engineered as a recombinant humanized monoclonal antibody (IgG1). Its exceptional mechanism targets epidermal growth factor receptors (EGFR), inhibiting tumor growth efficiently with reduced toxicity and low immunogenicity. Suitable for intravenous infusion, this prescription-only medication is indicated for various cancers, including head and neck malignancies and gliomas. Store refrigerated and protect from light for optimal efficacy.

Unique Features and Versatile Applications

Nimotuzumab Injection is distinguished by its humanized monoclonal antibody composition, offering high selectivity and minimized immunogenicity for enhanced patient safety. While its main application is in oncology, specifically against head and neck cancers, nasopharyngeal carcinoma, and glioma, it also serves in treating certain other epithelial cancers. The clear, colorless to pale yellow solution is administered intravenously, ensuring direct and controlled surface of application. Its odorless, preservative-stabilized formulation reflects advanced biotechnological expertise.

Domestic and International Market Reach

Our exceptional Nimotuzumab Injection is widely distributed across India, ensuring reliable access for healthcare providers nationwide. We prioritize swift dispatching processes and efficient goods transport for both domestic and export consignments. Internationally, we serve key markets with regulated compliance to support optimal patient outcomes. Sample policies are tailored to institutional requirements, and all expenditure and logistics follow stringent safety protocols, ensuring products arrive in perfect condition for immediate use.

FAQ's of Nimotuzumab Injection:

Q: How should Nimotuzumab Injection be administered?

A: Nimotuzumab Injection is administered via intravenous infusion by trained healthcare professionals under strict medical supervision to ensure optimal dosing and patient safety.

Q: What is the main mechanism of action of Nimotuzumab Injection?

A: Nimotuzumab binds specifically to the epidermal growth factor receptor (EGFR) on tumor cells, inhibiting their growth and proliferation, which makes it effective in oncology treatment.

Q: When is Nimotuzumab Injection indicated for use?

A: Nimotuzumab Injection is indicated for the treatment of certain head and neck cancers, glioma, nasopharyngeal carcinoma, and other selected epithelial cancers, as prescribed by a medical specialist.

Q: What precautions should be taken during Nimotuzumab administration?

A: This injection must be used only under strict medical supervision. It is contraindicated in patients with known hypersensitivity to Nimotuzumab or its components, and monitoring during infusion is necessary.

Q: Where should Nimotuzumab Injection be stored?

A: Nimotuzumab Injection should be stored at temperatures between 2C to 8C, protected from light, and must not be frozen to maintain its effectiveness and shelf life.

Q: What distinguishes Nimotuzumab Injection from enzyme-based therapies?

A: Nimotuzumab is a monoclonal antibody, not an enzyme. It offers targeted anticancer action with lowered toxicity and immunogenicity, distinguishing it from traditional enzyme therapies.

Tell us about your requirement